Skip to content
DataLookout
Menu

NCT05125146

Investigating the Effectiveness of E-CBTi Compared to Pharmaceutical Interventions in Treating Insomnia

StatusUnknown
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 5 versions: 5 with changes below.

  1. Minor Changed Registry marked status Unknown (sponsor has not verified the record since Oct 2024); last known: Recruiting
  2. Notable Primary completion date: Jul 21, 2024 to May 21, 2025
    • Study completion date: Dec 30, 2024 to Dec 30, 2025
    • Site contact updated
    v5
  3. Notable Lead sponsor: Queen's University to Dr. Nazanin Alavi
    • Primary completion date: Apr 21, 2023 to Jul 21, 2024
    • Study completion date: Jun 30, 2023 to Dec 30, 2024
    v4
  4. Minor Primary completion date: Dec 31, 2022 to Apr 21, 2023
    • Study completion date: Jan 30, 2023 to Jun 30, 2023
    v3
  5. Minor Secondary endpoints: details revised at 1 of 3 entriesv2
  6. Study First Submitted
  • Notable: the plan changed
  • Minor: routine updates

Endpoints

Primary

Insomnia Severity Index (ISI) - Change in Symptoms (Quantitative)
Timeframe: Baseline (week 0), mid-point (week 3-4), post-treatment (week 7)

Secondary (3)

Sleep Diary - Change in Sleep Quality
Sleep Diary - Change in Sleep quality
Behavioural Interactions- Change in Engagement

Arms and interventions

PharmacotherapyActive comparator

Trazodone is the treatment of choice for insomnia and participants allocated to the pharmaceutical intervention group will be prescribed trazodone as a regular treatment for the duration of the study. Participants on trazodone will also visit the psychiatrist every month to ensure their wellbeing is protected, the quality of the data is maintained, the conduct of the trial is in compliance with the approved protocol, and other regulatory requirements. Trazodone is the routine practice for insomnia and is covered through most patients' healthcare. However, if the patient does not have coverage for trazodone, they will be provided financial compensation to offset the cost.

e-CBTiExperimental

The e-CBTi modules will involve guiding participants to develop constructive and balanced strategies that would help to handle sleep problems. The e-CBTi program is based on the idea that insomnia is caused by thoughts and behaviours that can be changed. The modules aim to adjust negative thinking so patients can think about and adapt to the events that are happening to them, allowing them to adjust their behaviour and thoughts to be more realistic. Continuing, the modules are designed to help patients with insomnia deal with inaccurate thoughts about sleep and negative sleep behaviours, change their lifestyle practices that negatively affect their sleep, and improve relaxation skills to improve healthy sleep patterns. More specifically, the focus of the program is on addressing and exploring the concept of sleep, sleep habits, sleep hygiene, bedtime worries, negative thoughts, and thought examination.

Behavioral: e-CBTi

Drugs: Trazodone

Sites

1 site in 1 country

  • Queen's UniversityKingston, Ontario, Canada